AGEN Agenus Inc. - Common Stock
Acerca de Agenus Inc. - Common Stock Descripción general de la empresa de Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
Leer más
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
History
Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.
In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant
In April 2014, Agenus signed a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.
Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.
In August 2023, Agenus announced a strategic restructuring to prioritize its botensilimab and balstilimab (BOT/BAL) clinical programs. The plan included a 25% reduction in its workforce (approximately 85 positions) and the temporary suspension of most preclinical and clinical programs not related to the BOT/BAL combination. The company stated the reorganization was intended to reduce annual operating expenses by approximately $40 million.
In 2025, Agenus sold their CDMO business to Zydus Lifesciences including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Zydus to commercialize their molecules in India.
Key partners and deals
In April 2014, Agenus announced a collaboration and licensing agreement with Merck. The collaboration involved the discovery and development of therapeutic antibodies to two undisclosed Merck checkpoint targets, both thought to be relevant for cancer treatment, in addition to Agenus using its proprietary Retrocyte Display® platform to discover and optimize antibodies against the targets.
In February 2014, Agenus acquired European biotechnology firm 4-Antibody, along with its Retrocyte Display technology and a portfolio of checkpoint modulator antibody candidates .
In March 2012, GlaxoSmithKline acquired two extra rights in the two firms' agreement to use Agenus' QS-21 Stimulon adjuvant. The rights give GSK the first right in negotiation of purchase of Agenus or their assets, the rights expired in 2017 after five years had lapsed.
In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences valued at up to $141 million. Under the agreement, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to a new Zydus subsidiary, Zylidac Bio LLC, for an upfront payment of $75 million. The deal also included a $16 million equity investment by Zydus in Agenus common stock and up to $50 million in potential milestone payments. Additionally, Zydus obtained exclusive rights to develop and commercialize the botensilimab and balstilimab (BOT/BAL) combination therapy in India and Sri Lanka, with Agenus eligible for a 5% royalty on net sales. The transaction was formally closed in January 2026.
Product descriptions
Checkpoint modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer cells can evolve means to evade checkpoints, and CPMs can reverse that effect, helping the immune system better fight the cancer.
Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates. The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.
The Prophage series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors. Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has established a multi-product "good manufacturing practices" facility, which has already helped process over 1,000 tumor samples from across the globe.
The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces. Agenus has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, melanoma, and malaria. In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine with QS21-Stimulon. GSK stated that the treatment was working well enough to support a regulatory filing. RTS,S is the most advanced vaccine for malaria in development.
Agenus is the sole US-manufacturer of a patented and FDA-approved triterpene glycoside extract known as (QS-21, Matrix M), which is a key component in the manufacturing of the Oxford–AstraZeneca COVID-19 as well as the Novavax COVID-19 vaccines. Supplies are tightly controlled, and the US has invoked the US Defence Production Act to preserve vaccine raw materials for its own companies.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
AGEN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
AGEN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
AGEN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
- Compra fuerte 2 25,0%
- Compra 5 62,5%
- Mantener 1 12,5%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
2 analistas · 2026-08-16Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.01 | $0.05 | -0.06% |
| 31 de marzo de 2026 | $0.00 | $2.14 | -2.1% |
| 31 de diciembre de 2025 | $-0.31 | $-1.07 | 0.76% |
| 30 de septiembre de 2025 | $1.94 | $2.02 | -0.08% |
| 30 de junio de 2025 | $-1.00 | $1.38 | -2.4% |
| 31 de marzo de 2025 | $-1.03 | $-1.69 | 0.66% |
| 31 de diciembre de 2024 | $-2.04 | $-2.59 | 0.55% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| AGEN | $111M | — | 10.4% | -2.7% | 1.0% | — |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | — |
| RCKT | — | — | — | — | — | — |
| UPB | $1.47B | -10.2 | 20.4% | -5026.0% | -38.3% | — |
| IPSC | $87M | -7.1 | 1556.8% | -8.8% | -5.2% | — |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | — |
| PALI | $375M | -7.8 | — | — | -25.4% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Cost of Revenue | $1M | $486.0K | $3M | $11M | $3M | $2M | · | · | · | · | · | $0 | |
| R&D Expense | $79M | $156M | $235M | $187M | $179M | $143M | $168M | $125M | $116M | $95M | $70M | $22M | |
| SG&A Expense | $54M | $72M | $79M | $81M | $76M | $59M | $46M | $37M | $34M | $33M | $28M | $21M | |
| Operating Income | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | $-43M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Interest Income | $345.0K | $3M | $6M | $2M | · | · | · | · | · | · | · | · | |
| Other Non-op | $72M | $6M | $37.0K | $11M | $5M | $-2M | $28.0K | $-2M | $2M | $-2M | $-6M | $2M | |
| Pretax Income | $-3M | $-232M | $-257M | · | · | · | · | · | $-121M | $-127M | $-93M | $-42M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-5M | $0 | |
| Net Income | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | · | $-121M | $-127M | $-88M | $-42M | |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| Shares (Basic) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| Shares (Diluted) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| EBITDA | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | · |
Balance general 29
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $40M | $76M | $179M | $292M | $100M | $62M | $53M | $60M | $71M | $137M | $26M | |
| Short-term Investments | · | · | · | $15M | $15M | · | · | · | · | $5M | $35M | $15M | |
| Receivables | $2M | $407.0K | $26M | $3M | $2M | $1M | $16M | $938.0K | $1M | $11M | $10M | $463.0K | |
| Inventory | · | · | · | · | · | · | $0 | $55.0K | $79.5K | $88.2K | $88.2K | $95.7K | |
| Prepaid Expense | $785.0K | $2M | $8M | $14M | $20M | $11M | $7M | $19M | $11M | $3M | $2M | $1M | |
| Other Current Assets | $1M | $2M | $2M | $3M | $3M | $2M | $1M | $1M | $1M | $838.5K | $582.3K | $640.0K | |
| Current Assets | $133M | $46M | $112M | $213M | $332M | $114M | $87M | $75M | $74M | $91M | $184M | $43M | |
| PP&E (Net) | $15M | $120M | $133M | $133M | $60M | $27M | $26M | $25M | $26M | $26M | $15M | $6M | |
| PP&E (Gross) | $63M | $193M | $195M | $187M | $111M | $74M | $69M | $63M | $60M | $57M | $45M | $34M | |
| Accum. Depreciation | $47M | $73M | $62M | $54M | $51M | $47M | $43M | $38M | $34M | $31M | $29M | $28M | |
| Goodwill | $24M | $24M | $25M | $25M | $25M | $25M | $23M | $23M | $23M | $22M | $23M | $18M | |
| Intangibles | $3M | $3M | $4M | $6M | $8M | $11M | $11M | $12M | $14M | $16M | $19M | $7M | |
| Other Non-current Assets | $3M | $6M | $9M | $4M | $10M | $4M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Accounts Payable | $83M | $61M | $61M | $41M | $30M | $17M | $14M | $14M | $8M | $5M | $4M | $2M | |
| Accrued Liabilities | $34M | $35M | $45M | $38M | $42M | $29M | $31M | $25M | $22M | $28M | $14M | $6M | |
| Current Liabilities | $323M | $221M | $256M | $189M | $157M | $130M | $122M | $68M | $56M | $41M | $29M | $9M | |
| Capital Leases | $10M | $55M | $63M | $63M | $42M | $34M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $259.0K | $738.0K | $5M | $15M | $2M | $2M | $4M | $3M | $3M | $5M | $8M | $3M | |
| Long-term Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | $6M | |
| Total Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | · | |
| Common Stock | $353.0K | $236.0K | $197.0K | $3M | $3M | $2M | $1M | $1M | $1M | $877.9K | $863.9K | $627.2K | |
| Paid-in Capital | $1.91B | $1.86B | $1.80B | $1.64B | $1.52B | $1.26B | $1.06B | $1.01B | $952M | $867M | $851M | $716M | |
| Retained Earnings | $-2.18B | $-2.18B | $-1.96B | $-1.71B | $-1.49B | $-1.47B | $-1.28B | $-1.18B | $-1.03B | $-905M | $-779M | $-691M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| AOCI | $-439.0K | $-1M | $-955.0K | $915.0K | $1M | $3M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $-271M | $-326M | $-160M | $-61M | $34M | $-204M | $-225M | $-172M | $-76M | $-39M | $71M | $23M | |
| Liabilities + Equity | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Shares Outstanding | 35,320,397 | 23,634,670 | 19,718,662 | · | · | · | · | · | · | · | · | · |
Flujo de Efectivo 12
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $13M | $14M | $7M | $7M | $7M | $7M | $6M | $6M | $5M | $2M | $2M | |
| Stock-based Comp | $14M | $17M | $23M | $18M | $20M | $10M | $10M | $8M | $12M | $13M | $7M | $5M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | · | $-5M | · | |
| Amort. of Intangibles | $300.0K | $500.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $462.0K | |
| Operating Cash Flow | $-77M | $-158M | $-224M | $-175M | $10M | $-139M | $-19M | $-131M | $-94M | $-80M | $-47M | $-38M | |
| CapEx | $6.0K | $576.0K | $10M | $53M | $34M | $3M | $5M | $4M | $3M | $13M | $4M | $3M | |
| Investing Cash Flow | $1M | $27.0K | $3M | $-34M | $-43M | $-4M | $-5M | $-4M | $2M | $18M | · | $-17M | |
| Debt Issued | · | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Net Debt Issued | $-2M | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Financing Cash Flow | $37M | $123M | $120M | $96M | $225M | $184M | $31M | $128M | $81M | $-2M | · | $53M | |
| Net Change in Cash | $-39M | $-36M | $-102M | $-113M | $192M | $41M | $9M | $-7M | $-11M | $-65M | $111M | $-2M | |
| Free Cash Flow | $-77M | $-159M | $-234M | $-228M | $-24M | $-143M | $-23M | $-135M | $-97M | $-92M | $-51M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| Net Margin | -2.7% | -224.5% | -164.7% | -235.3% | -9.7% | · | · | · | -281.5% | -562.6% | -354.1% | · | |
| Pretax Margin | -2.7% | · | · | · | · | · | · | · | -281.5% | -562.6% | -375.8% | · | |
| EBITDA Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| ROA | -1.4% | -86.0% | -70.8% | -52.4% | -8.4% | · | · | · | -81.7% | -63.6% | -55.5% | · | |
| ROE | 1.0% | 95.5% | 232.3% | 1718.9% | 34.0% | · | · | · | 210.0% | -803.7% | -187.5% | · | |
| ROIC | 8.9% | · | · | · | · | · | · | · | -119.0% | -117.4% | -41.1% | · |
Liquidez y Solvencia 4
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 | 0.9 | 0.7 | 1.1 | 1.3 | 2.2 | 6.4 | · | |
| Quick Ratio | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 | 0.8 | 0.6 | 0.8 | 1.1 | 2.1 | 6.3 | · | |
| Debt / Equity | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -2.2 | -3.3 | 1.6 | · | |
| LT Debt / Equity | 0.0 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -1.9 | -3.3 | 1.6 | · |
Eficiencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.9 | 0.5 | 1.0 | 0.3 | 0.3 | 0.1 | 0.2 | · | |
| Receivables Turnover | 102.1 | 7.9 | 10.9 | 46.0 | 221.1 | 10.1 | 17.4 | 35.5 | 6.9 | 2.1 | 4.8 | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.4% | -33.8% | 59.5% | -66.8% | 235.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | -29.5% | 21.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 13
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Net Income TTM | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | $-162M | $-121M | $-127M | $-88M | $-42M | |
| Market Cap | $111M | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $153M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | -0.3 | -1.2 | -3.0 | -574.5 | -59.4 | -98.6 | · | -56.6 | -71.6 | -78.9 | -69.0 | |
| P/S | 1.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | -0.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -7.6 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.0 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 1.3 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -386.5% | -82.8% | -33.2% | -0.17% | -1.7% | -1.0% | · | -1.8% | -1.4% | -1.3% | -1.5% |
Estado de resultados 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | $34M | $30M | $26M | $24M | $27M | $25M | $24M | $28M | $84M | $24M | $25M | $23M | $28M | $23M | |
| Cost of Revenue | $0 | $0 | $0 | $642.0K | $243.0K | $137.0K | $118.0K | $146.0K | $115.0K | $107.0K | $260.0K | $303.0K | $254.0K | $2M | $8M | $308.0K | |
| R&D Expense | $15M | $12M | $8M | $24M | $27M | $22M | $34M | $41M | $37M | $44M | $67M | $51M | $59M | $57M | $53M | $46M | |
| SG&A Expense | $8M | $7M | $12M | $11M | $16M | $16M | $21M | $17M | $17M | $17M | $21M | $19M | $20M | $18M | $25M | $18M | |
| Operating Expenses | $23M | $19M | · | · | $42M | $37M | · | · | · | · | · | · | · | · | · | · | |
| Operating Income | $11M | $15M | $14M | $-5M | $-17M | $-13M | $-26M | $-32M | $-30M | $-33M | $-4M | $-46M | $-55M | $-54M | $-58M | $-42M | |
| Interest Income | $121.0K | $21.0K | $29.0K | $74.0K | $54.0K | $188.0K | $429.0K | $1M | $539.0K | $808.0K | · | · | · | · | · | · | |
| Other Non-op | $3M | $39M | $-9M | $82M | $-12.0K | $-264.0K | $-224.0K | $19.0K | $7M | $-1M | $-201.0K | $442.0K | $-244.0K | $40.0K | $980.0K | $537.0K | |
| Net Income | $-567.0K | $39M | $-11M | $64M | $-30M | $-26M | $-47M | $-67M | $-55M | $-63M | $-49M | $-65M | $-73M | $-71M | $-74M | $-57M | |
| EPS (Basic) | $-0.01 | $1.03 | $0.03 | $2.00 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| EPS (Diluted) | $-0.01 | $1.02 | $0.09 | $1.94 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| Shares (Basic) | 41,338,000 | 37,941,000 | -54,738,000 | 31,886,000 | 28,117,000 | 24,469,000 | -41,507,000 | 21,550,000 | 21,062,000 | 20,368,000 | -34,438,000 | 18,908,000 | 17,569,000 | 15,855,000 | 13,264,803 | 286,854 | |
| Shares (Diluted) | 41,338,000 | 38,285,000 | -55,710,000 | 32,858,000 | 28,117,000 | 24,469,000 | -41,507,000 | 21,550,000 | 21,062,000 | 20,368,000 | -34,438,000 | 18,908,000 | 17,569,000 | 15,855,000 | 13,264,803 | 286,854 | |
| EBITDA | $11M | $15M | · | $-5M | $-17M | $-13M | · | $-32M | $-30M | $-33M | · | $-46M | $-55M | $-54M | · | $-42M |
Balance general 27
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M | $94M | $53M | $76M | $106M | $143M | $165M | $179M | $208M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | $15M | $24M | · | $10M | |
| Receivables | $15M | $7M | $2M | $538.0K | $709.0K | $354.0K | $407.0K | $207.0K | $719.0K | $476.0K | · | $1M | $1M | $1M | · | $9M | |
| Prepaid Expense | $3M | $4M | $785.0K | $885.0K | $1M | $2M | $2M | $2M | $2M | $4M | · | $16M | $9M | $11M | · | $22M | |
| Other Current Assets | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | · | $2M | $3M | $4M | · | $2M | |
| Current Assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M | $100M | $60M | · | $126M | $171M | $206M | · | $251M | |
| PP&E (Net) | $14M | $15M | $15M | $16M | $113M | $117M | $120M | $124M | $128M | $130M | · | $140M | $143M | $140M | · | $101M | |
| PP&E (Gross) | · | · | $63M | · | · | · | $193M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $48M | $48M | $47M | $47M | $75M | $76M | $73M | $71M | $68M | $65M | · | $61M | $58M | $56M | · | $53M | |
| Goodwill | $24M | $24M | $24M | $24M | $24M | $24M | $24M | $25M | $25M | $25M | · | $25M | $25M | $26M | · | $24M | |
| Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | $4M | $5M | $6M | · | $7M | |
| Other Non-current Assets | $4M | $3M | $3M | $3M | $5M | $6M | $6M | $7M | $7M | $8M | · | $11M | $9M | $4M | · | $8M | |
| Total Assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Accounts Payable | $59M | $71M | $83M | $85M | $74M | $64M | $61M | $46M | $51M | $51M | · | $41M | $52M | $47M | · | $40M | |
| Accrued Liabilities | $28M | $37M | $34M | $32M | $39M | $36M | $35M | $37M | $41M | $41M | · | $38M | $30M | $33M | · | $29M | |
| Current Liabilities | $232M | $249M | $323M | $287M | $235M | $208M | $221M | $271M | $271M | $256M | · | $198M | $204M | $191M | · | $173M | |
| Capital Leases | $10M | $10M | $10M | $10M | $53M | $54M | $55M | $55M | $56M | $62M | · | $63M | $62M | $63M | · | $64M | |
| Other Non-current Liabilities | $247.0K | $247.0K | $259.0K | $376.0K | $752.0K | $761.0K | $738.0K | $777.0K | $1M | $3M | · | $8M | $11M | $14M | · | $1M | |
| Long-term Debt | $30M | $30M | $45M | $34M | $34M | $34M | $33M | $13M | $13M | $14M | · | $13M | $13M | $14M | · | · | |
| Total Debt | $30M | $30M | · | $34M | $34M | $34M | · | $13M | $13M | $14M | · | $13M | $13M | $14M | · | $13M | |
| Common Stock | $427.0K | $385.0K | $353.0K | $329.0K | $300.0K | $266.0K | $236.0K | $217.0K | $211.0K | $210.0K | · | $4M | $4M | $3M | · | $3M | |
| Paid-in Capital | $1.95B | $1.92B | $1.91B | $1.90B | $1.88B | $1.87B | $1.86B | $1.85B | $1.83B | $1.82B | · | $1.78B | $1.75B | $1.72B | · | $1.61B | |
| Retained Earnings | $-2.14B | $-2.14B | $-2.18B | $-2.17B | $-2.24B | $-2.21B | $-2.18B | $-2.14B | $-2.07B | $-2.02B | · | $-1.91B | $-1.85B | $-1.78B | · | $-1.64B | |
| AOCI | $-450.0K | $-437.0K | $-439.0K | $-2M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | · | $-1M | $-717.0K | $917.0K | · | $644.0K | |
| Stockholders' Equity | $-199M | $-221M | $-271M | $-274M | $-355M | $-342M | $-326M | $-292M | $-241M | $-201M | · | $-129M | $-93M | $-59M | · | $-20M | |
| Liabilities + Equity | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Shares Outstanding | 42,615,618 | 38,521,761 | 35,320,397 | 32,814,429 | 30,004,430 | 26,563,545 | 23,634,670 | 21,685,192 | 21,126,226 | 20,994,143 | · | · | · | · | · | · |
Flujo de Efectivo 9
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $517.0K | $583.0K | $597.0K | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $4M | $1M | $3M | $3M | $4M | $3M | $5M | $5M | $4M | $4M | $5M | $6M | $6M | $5M | $4M | $4M | |
| Operating Cash Flow | $-31M | $-36M | $-17M | $-15M | $-20M | $-26M | $-29M | $-53M | $-38M | $-38M | $-40M | $-65M | $-60M | $-59M | $-47M | $-32M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $5.0K | $73.0K | $7.0K | $461.0K | $35.0K | $223.0K | $3M | $4M | $2M | $14M | $16M | |
| Investing Cash Flow | $267.0K | $69M | $780.0K | $76.0K | $281.0K | $57.0K | $-21.0K | $56.0K | $-237.0K | $229.0K | $3M | $12M | $517.0K | $-11M | $-6M | $-16M | |
| Net Debt Issued | · | $-8M | · | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $-993.0K | $15M | $7M | $11M | $4M | $24M | $5M | $79M | $15M | $7M | $18M | $38M | $56M | $24M | $28M | |
| Net Change in Cash | $-16M | $32M | $-460.0K | $-8M | $-9M | $-22M | $-4M | $-49M | $41M | $-23M | $-30M | $-36M | $-22M | $-14M | $-30M | $-20M | |
| Free Cash Flow | · | $-36M | · | · | · | $-26M | · | · | · | $-38M | · | · | · | $-60M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| Net Margin | -1.6% | 116.2% | · | 211.4% | -116.8% | -109.6% | · | -267.7% | -233.1% | -226.6% | · | -265.4% | -290.3% | -309.6% | · | -249.1% | |
| EBITDA Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| ROA | -0.32% | 20.3% | · | 27.1% | -12.6% | -11.6% | · | -23.4% | -16.2% | -19.0% | · | -16.9% | -17.5% | -16.6% | · | -13.1% | |
| ROE | 0.20% | -13.9% | · | -22.6% | 10.1% | 9.7% | · | 31.9% | 32.8% | 48.8% | · | 86.3% | 163.6% | 331.1% | · | -528.3% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | 0.4 | · | 0.5 | 0.1 | 0.1 | · | 0.2 | 0.4 | 0.2 | · | 0.6 | 0.8 | 1.1 | · | 1.5 | |
| Quick Ratio | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.1 | · | 0.2 | 0.3 | 0.2 | · | 0.5 | 0.8 | 1.0 | · | 1.3 | |
| Debt / Equity | -0.2 | -0.1 | · | -0.1 | -0.1 | -0.1 | · | -0.0 | -0.1 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.7 | |
| LT Debt / Equity | · | · | · | -0.1 | -0.1 | -0.1 | · | 0.0 | 0.0 | 0.0 | · | -0.1 | -0.1 | -0.2 | · | · |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 4.5 | 9.8 | · | 81.2 | 36.0 | 58.0 | · | 40.6 | 22.8 | 29.6 | · | 4.9 | 2.5 | 16.9 | · | 1.5 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $124M | $114M | · | $105M | $98M | $101M | · | $101M | $101M | $101M | · | $95M | $92M | $93M | · | $323M | |
| Net Income TTM | $73M | $47M | · | $-60M | $-178M | $-212M | · | $-250M | $-256M | $-272M | · | $-266M | $-250M | $-227M | · | $21M | |
| Market Cap | $130M | $129M | · | $126M | $137M | $40M | · | $119M | $354M | $244M | · | · | · | · | · | · | |
| Enterprise Value | $142M | $124M | · | $157M | $161M | $55M | · | $87M | $274M | $204M | · | · | · | · | · | · | |
| P/E | 1.6 | 3.6 | · | -1.2 | -0.6 | -0.2 | · | -0.5 | -1.3 | -0.8 | · | -1.9 | -3.7 | -6.1 | · | 236.7 | |
| P/S | 1.1 | 1.1 | · | 1.2 | 1.4 | 0.4 | · | 1.2 | 3.5 | 2.4 | · | · | · | · | · | · | |
| P/B | -0.7 | -0.6 | · | -0.5 | -0.4 | -0.1 | · | -0.4 | -1.5 | -1.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| P / FCF | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| EV / EBITDA | 12.6 | 8.2 | · | -34.6 | -9.7 | -4.1 | · | -2.8 | -9.1 | -6.2 | · | · | · | · | · | · | |
| EV / FCF | · | -3.4 | · | · | · | -2.2 | · | · | · | -5.3 | · | · | · | · | · | · | |
| EV / Revenue | 1.1 | 1.1 | · | 1.5 | 1.6 | 0.5 | · | 0.9 | 2.7 | 2.0 | · | · | · | · | · | · | |
| Earnings Yield | 63.7% | 27.8% | · | -82.3% | -167.0% | -640.4% | · | -217.7% | -76.3% | -125.6% | · | -51.9% | -26.9% | -16.3% | · | 0.42% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $114M | $103M | $156M | $98M | $296M |
| Margen Operativo % | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% |
| Beneficio neto | $-3M | $-232M | $-257M | $-231M | $-29M |
| EPS Diluido | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 |
| Ratio corriente | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 |
| Ratio Rápido | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-77M | $-159M | $-234M | $-228M | $-24M |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 117 declarantes · $30.7M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 37 (+23 vs trimestre anterior) | 14 (-3 vs trimestre anterior) | 27 (+7 vs trimestre anterior) | 22 (-6 vs trimestre anterior) | +2.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5 128 854 | 1 676 096 | 16,71% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4 368 416 | 1 427 587 | 14,23% | Acciones |
| Siren, L.L.C. | $3 256 605 | 1 064 250 | 10,61% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $2 731 786 | 892 458 | 8,90% | Acciones |
| MACKENZIE FINANCIAL CORP | $2 185 376 | 714 175 | 7,12% | Acciones |
| GLOBEFLEX CAPITAL L P | $1 280 858 | 418 581 | 4,17% | Acciones |
| STATE STREET CORP | $1 261 892 | 412 383 | 4,11% | Acciones |
| Man Group plc | $1 041 701 | 340 425 | 3,39% | Acciones |
| GOLDMAN SACHS GROUP INC | $1 017 753 | 332 599 | 3,32% | Acciones |
| Connor, Clark & Lunn Investment Management Ltd. | $948 707 | 310 035 | 3,09% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $831 139 | 271 614 | 2,71% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $698 739 | 228 346 | 2,28% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $549 542 | 179 589 | 1,79% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $485 735 | 158 737 | 1,58% | Acciones |
| Cubist Systematic Strategies, LLC | $393 512 | 102 211 | 1,28% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $304 140 | 99 392 | 0,99% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $301 976 | 98 685 | 0,98% | Acciones |
| STRS OHIO | $235 314 | 76 900 | 0,77% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $205 326 | 67 100 | 0,67% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $128 569 | 42 016 | 0,42% | Acciones |
| Avestar Capital, LLC | $125 460 | 41 000 | 0,41% | Acciones |
| BlackRock, Inc. | $124 756 | 40 770 | 0,41% | Acciones |
| DEUTSCHE BANK AG\ | $119 046 | 38 904 | 0,39% | Acciones |
| Bank of New York Mellon Corp | $115 998 | 37 908 | 0,38% | Acciones |
| MARSHALL WACE, LLP | $109 602 | 35 818 | 0,36% | Acciones |
| TWO SIGMA ADVISERS, LP | $107 529 | 34 245 | 0,35% | Acciones |
| Claro Advisors Inc. | $102 051 | 33 350 | 0,33% | Acciones |
| XTX Topco Ltd | $96 849 | 31 650 | 0,32% | Acciones |
| CITADEL ADVISORS LLC | $90 270 | 29 500 | 0,29% | Opción de compra |
| RHUMBLINE ADVISERS | $90 226 | 29 488 | 0,29% | Acciones |
| CAPTRUST FINANCIAL ADVISORS | $88 654 | 28 972 | 0,29% | Acciones |
| BANK OF AMERICA CORP /DE/ | $87 354 | 28 547 | 0,28% | Acciones |
| Engineers Gate Manager LP | $85 092 | 27 808 | 0,28% | Acciones |
| CITIGROUP INC | $77 733 | 25 403 | 0,25% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $77 418 | 25 300 | 0,25% | Opción de compra |
| LPL Financial LLC | $73 948 | 24 166 | 0,24% | Acciones |
| Key Client Fiduciary Advisors, LLC | $73 823 | 24 125 | 0,24% | Acciones |
| OSAIC HOLDINGS, INC. | $71 774 | 23 456 | 0,23% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $67 002 | 21 896 | 0,22% | Acciones |
| WOLVERINE TRADING, LLC | $63 282 | 15 900 | 0,21% | Opción de compra |
| CITADEL ADVISORS LLC | $62 730 | 20 500 | 0,20% | Opción de venta |
| PRELUDE CAPITAL MANAGEMENT, LLC | $60 469 | 19 761 | 0,20% | Acciones |
| PRUDENTIAL FINANCIAL INC | $59 395 | 19 410 | 0,19% | Acciones |
| Vanguard Personalized Indexing Management, LLC | $58 749 | 19 199 | 0,19% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $57 834 | 18 900 | 0,19% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $56 916 | 18 600 | 0,19% | Opción de venta |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $56 142 | 18 347 | 0,18% | Acciones |
| UBS Group AG | $52 825 | 17 263 | 0,17% | Acciones |
| VANGUARD GROUP INC | $49 945 | 15 906 | 0,16% | Acciones |
| Vanguard Global Advisers, LLC | $48 672 | 15 906 | 0,16% | Acciones |
| Invesco Ltd. | $48 620 | 15 889 | 0,16% | Acciones |
| SHERBROOKE PARK ADVISERS LLC | $48 325 | 15 390 | 0,16% | Acciones |
| DIVERSIFIED TRUST CO | $47 677 | 15 581 | 0,16% | Acciones |
| BANK OF MONTREAL /CAN/ | $47 207 | 15 427 | 0,15% | Acciones |
| Police & Firemen's Retirement System of New Jersey | $46 947 | 15 342 | 0,15% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $41 349 | 12 380 | 0,13% | Acciones |
| R Squared Ltd | $41 068 | 13 421 | 0,13% | Acciones |
| FMR LLC | $40 582 | 13 262 | 0,13% | Acciones |
| Post Resch Tallon Group Inc. | $39 015 | 12 750 | 0,13% | Acciones |
| StoneX Group Inc. | $36 849 | 10 728 | 0,12% | Acciones |
| Abel Hall, LLC | $35 986 | 11 760 | 0,12% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $35 707 | 11 669 | 0,12% | Acciones |
| Graham Capital Management, L.P. | $35 052 | 11 455 | 0,11% | Acciones |
| HSBC HOLDINGS PLC | $34 757 | 11 176 | 0,11% | Acciones |
| MORGAN STANLEY | $34 070 | 11 134 | 0,11% | Acciones |
| Values First Advisors, Inc. | $33 612 | 10 984 | 0,11% | Acciones |
| ZACKS INVESTMENT MANAGEMENT | $32 285 | 10 550 | 0,11% | Acciones |
| JANE STREET GROUP, LLC | $31 824 | 10 400 | 0,10% | Opción de compra |
| Point72 Asia (Singapore) Pte. Ltd. | $31 366 | 8 147 | 0,10% | Acciones |
| EP Wealth Advisors, LLC | $30 600 | 10 000 | 0,10% | Acciones |
| NORTHERN TRUST CORP | $18 902 | 6 177 | 0,06% | Acciones |
| BARCLAYS PLC | $17 950 | 5 866 | 0,06% | Acciones |
| Legal & General Group Plc | $11 824 | 3 864 | 0,04% | Acciones |
| Ameritas Investment Partners, Inc. | $11 065 | 3 616 | 0,04% | Acciones |
| FEDERATED HERMES, INC. | $10 343 | 3 380 | 0,03% | Acciones |
| Pinnacle Wealth Planning Services, Inc. | $10 321 | 3 373 | 0,03% | Acciones |
| Russell Investments Group, Ltd. | $9 733 | 3 181 | 0,03% | Acciones |
| Tower Research Capital LLC (TRC) | $7 072 | 2 311 | 0,02% | Acciones |
| CoreCap Advisors, LLC | $6 120 | 2 000 | 0,02% | Acciones |
| Atlantic Union Bankshares Corp | $5 355 | 1 750 | 0,02% | Acciones |
| Caitong International Asset Management Co., Ltd | $4 997 | 1 633 | 0,02% | Acciones |
| ROYAL BANK OF CANADA | $4 000 | 1 360 | 0,01% | Acciones |
| Jump Financial, LLC | $3 614 | 1 181 | 0,01% | Acciones |
| CHILTON CAPITAL MANAGEMENT LLC | $3 238 | 1 058 | 0,01% | Acciones |
| CWM, LLC | $2 739 | 820 | 0,01% | Acciones |
| NISA INVESTMENT ADVISORS, LLC | $2 592 | 847 | 0,01% | Acciones |
| Sterling Capital Management LLC | $2 157 | 705 | 0,01% | Acciones |
| HUNTINGTON NATIONAL BANK | $2 032 | 664 | 0,01% | Acciones |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $1 937 | 633 | 0,01% | Acciones |
| Physician Wealth Advisors, Inc. | $1 901 | 621 | 0,01% | Acciones |
| Game Plan Financial Advisors, LLC | $1 790 | 585 | 0,01% | Acciones |
| Optiver Holding B.V. | $1 756 | 574 | 0,01% | Acciones |
| GROUP ONE TRADING LLC | $1 717 | 561 | 0,01% | Acciones |
| JPMORGAN CHASE & CO | $1 203 | 382 | 0,00% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $952 | 285 | 0,00% | Acciones |
| Rialto Wealth Management, LLC | $934 | 305 | 0,00% | Acciones |
| WELLS FARGO & COMPANY/MN | $704 | 230 | 0,00% | Acciones |
| Bare Financial Services, Inc | $529 | 173 | 0,00% | Acciones |
| Bogart Wealth, LLC | $523 | 171 | 0,00% | Acciones |
| Sandy Spring Bank | $377 | 250 | 0,00% | Acciones |
Informantes de la empresa 46 insiders · 7 directivos · 4 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Jeff D Clark | Chief Financial Officer | 18 de febrero de 2004 A | — | 0 | 0 | $0 |
| Austin Charette | Principal Accounting Officer | 24 de abril de 2026 A | — | 0 | 0 | $0 |
| Christine M Klaskin | PFO & PAO | 18 de junio de 2025 A | 23 478 | 0 | 0 | $0 |
| Evan Kearns | Vice President and General Counsel | 24 de diciembre de 2019 A | — | 0 | 0 | $0 |
| Christian Cortis | Chief Strategy Officer & Head of Finance | 19 de junio de 2019 A | — | 0 | 0 | $0 |
| Alex Duncan | Chief Technology Officer | 19 de junio de 2019 A | 21 026 | 0 | 0 | $0 |
| Neal Gordon | SrVP, Manufacturing Operations | 18 de febrero de 2004 A | — | 0 | 0 | $0 |
| Ulf Wiinberg | Consejero | 1 de octubre de 2024 A | 124 063 | 0 | 0 | $0 |
| Allison M Jeynes-Ellis | Consejero | 5 de febrero de 2024 A | 66 176 | 0 | 0 | $0 |
| Wadih Jordan | Consejero | 3 de octubre de 2022 A | — | 0 | 0 | $0 |
| Paul N Clark | Consejero | 27 de agosto de 2020 A | — | 0 | 0 | $0 |
| AGENUS INC | Propietario del 10% | 16 de octubre de 2023 P | 21 772 863 | 0 | 0 | $0 |
| INCYTE CORP | Propietario del 10% | 17 de junio de 2020 S | 16 972 968 | 0 | 0 | $0 |
| Brad M Kelley | Propietario del 10% | 24 de septiembre de 2003 P | 5 546 740 | 0 | 0 | $0 |
| Garo H Armen | — | 10 de agosto de 2026 A | 371 108 | 0 | 0 | $0 |
| Steven J O'Day | — | 5 de agosto de 2026 A | 57 116 | 0 | 0 | $0 |
| Susan B Hirsch | — | 5 de agosto de 2026 A | 108 725 | 0 | 0 | $0 |
| Jennifer Buell | — | 5 de agosto de 2026 A | 19 738 | 0 | 0 | $0 |
| Brian Corvese | — | 5 de agosto de 2026 A | 92 085 | 0 | 0 | $0 |
| Timothy Wright | — | 5 de agosto de 2026 A | 50 391 | 0 | 0 | $0 |
| Thomas L Harrison | — | 5 de agosto de 2026 A | 47 545 | 0 | 0 | $0 |
| Adam Krauss | — | 15 de junio de 2021 A | — | 0 | 0 | $0 |
| Shalini Sharp | — | 21 de junio de 2018 A | 104 270 | 0 | 0 | $0 |
| Ozer Baysal | — | 20 de junio de 2018 A | 58 790 | 0 | 0 | $0 |
| Karen Valentine | — | 20 de junio de 2018 A | 101 521 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | — | 31 de marzo de 2017 A | — | 0 | 0 | $0 |
| Robert Benjamin Stein | — | 31 de marzo de 2017 A | 20 986 | 0 | 0 | $0 |
| Shahzad Malik | — | 15 de junio de 2016 A | 1 587 302 | 0 | 0 | $0 |
| Charles Evan Ballantyne | — | 14 de junio de 2016 A | 24 795 | 0 | 0 | $0 |
| Tom Dechaene | — | 4 de enero de 2016 A | — | 0 | 0 | $0 |
| Kerry Wentworth | — | 26 de febrero de 2014 S | 57 410 | 0 | 0 | $0 |
| John Hatsopoulos | — | 3 de octubre de 2011 A | 65 000 | 0 | 0 | $0 |
| ROTHWELL TIMOTHY G | — | 3 de octubre de 2011 J | 7 389 | 0 | 0 | $0 |
| Hyam Levitsky | — | 1 de julio de 2011 A | 15 376 | 0 | 0 | $0 |
| Peter Thornton | — | 5 de junio de 2008 A | 5 000 | 0 | 0 | $0 |
| Eisen Margaret | — | 5 de junio de 2008 A | 20 000 | 0 | 0 | $0 |
| AFEYAN NOUBAR | — | 2 de abril de 2007 A | 0 | 0 | 0 | $0 |
| ATLEE FRANK V III | — | 2 de abril de 2007 A | 0 | 0 | 0 | $0 |
| Pramod Srivastava | — | 9 de febrero de 2007 S | 1 610 | 0 | 0 | $0 |
| Roman Chicz | — | 5 de enero de 2007 A | — | 0 | 0 | $0 |
| Mark Kessel | — | 2 de octubre de 2006 A | — | 0 | 0 | $0 |
| Bruce Leicher | — | 15 de septiembre de 2006 A | — | 0 | 0 | $0 |
| Alastair Jj Wood | — | 15 de junio de 2006 A | — | 0 | 0 | $0 |
| Gamil De Chadarevian | — | 28 de febrero de 2006 M | 88 610 | 0 | 0 | $0 |
| Renu Gupta | — | 24 de febrero de 2006 A | — | 0 | 0 | $0 |
| Russell Herndon | — | 8 de diciembre de 2004 A | — | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 5 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| ZYNEXT VENTURES USA LLC, ZYNEXT VENTURES PTE LTD, ZYDUS LIFESCIENCES LTD | 23 de enero de 2026 | 5,90% | Presentación inicial | — | SEC |
| Agenus Inc. (“Agenus”) ×3 presentaciones | 26 de mayo de 2023 | — | Presentación inicial | Inversión pasiva | SEC |
| Garo H. Armen | 22 de enero de 2008 | — | Presentación inicial | Inversión pasiva | SEC |
| Brad M. Kelley 2) ×4 presentaciones | 27 de febrero de 2003 | — | Presentación inicial | — | SEC |
| Persona informante no revelada | 1 de mayo de 2001 | — | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 11 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | — | — | 15 de julio de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 de julio de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de julio de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de julio de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de julio de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 de julio de 2026 | Diario |
| IWN · iShares Trust | — | — | 17 de agosto de 2026 | Diario |
| IWO · iShares Trust | — | — | 18 de agosto de 2026 | Diario |
| IWM · iShares Trust | — | — | 18 de agosto de 2026 | Diario |
| IWC · iShares Trust | — | — | 18 de agosto de 2026 | Diario |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 5 de agosto de 2026 | Diario |